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ABSTRACT

The effects of the kappa opioid agonist U-50,488 on morphineinduced conditioned place preference (GPP), locomotor

activity and Fos immunoreactivity was assessed in 10-, 17

and 35-day-old rats.

It was predicted that kappa agonist

treatment would block the unconditioned and conditioned

behaviors produced by morphine (a mu opioid receptor

agonist).

Conditioning and testing for the preweanling and

periadolescent (35-day-olds) rats were conducted in a three

compartment chamber consisting of two large end compartments
and a smaller middle chamber. Each end compartment had its

own distinct tactile and odor cues.

Conditioning took place

over two days followed by a test day.

In Experiment 1, 17

day-old rats received saline only and were placed in a
compartment scented with 10 cc lemon or almond extract.

On

the second conditioning day, rats were treated with morphine
(0.1, 0.2 and 0.5 mg/kg, i.p.) or saline, and then placed in
the opposite compartment scented with 10 cc lemon or almond

extract.
days.

The scents were counterbalanced across conditioning

In Experimental 2, the procedure was identical with

the exception that the 17-day-old rats were injected with U

50,488 (2.0, 5.0 and 10 mg/kg, s.c.) or saline 30 min prior
to morphine (0.5 mg/kg, i.p.). In Experiment 3, 10-, 17-,
and 35-day-old rats received U-50,488 (2.0 mg/kg, s.c.) 30
min prior to morphine conditioning.

111

The results of

Experiment 1 showed that morphine (0.5 mg/kg) produced a
place preference in 17-day-old rats without inducing

hyperactivity.

In Experiment 2, U-50,488 blocked morphine-

induced CPP while increasing locomotor activity.

Results

from Experiment 3 showed that morphine produced CPP in the

10- and 17-day-old rats, and that U-50,488 successfully
blocked this morphine-induced effect.

Surprisingly, U-50,488

produced hyperactivity in the 10- and 17-day-ols, while

increasing rearing and wall climbing in the 10-day-old rats,
an effect partially blocked by morphine.

Morphine or U

50,488 did not affect either the place preference

conditioning or the locomotor activity of the 35-day-old
rats.

Two hours after CPP testing, rats were sacrificed and

Eos immunoreactivity was assessed (Experiment 4).

Young rats

showed Eos activity in the dorsomedial thalamus, posterior
hypothalamus, and the habenula: results not consistent with

adults.

When taken together, these results indicate that

morphine.is rewarding in preweanling rats without inducing
locomotor activity.

Eurthermore, these results demonstrate

that U-50,488 have opposite profiles of action in the

developing rat when compared to adult rats.

Thus, it appears

that U-50,488 enhances DA functioning in the preweanling rat
while it depresses DA functioning in the adult rat.

These

age-dependent differences in behavioral response may be used
for further understanding how the kappa opioid and DA system
interact.
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INTRODUCTION,

Drug abuse and addiction are. serious sociomedical

problems in our society.

One of the most abused classes of

drugs are the psychomotor stimulants, which includes both

cocaine and amphetamine (Wise & Bozarth, 1987).

Users of

psychomotor stimulants report being swept by feelings of
well-being; they feel self-confident, energetic, alert,
friendly, outgoing, and they have less desire for food and
sleep (Gawin, 1991).

Another class of .abused drugs are the opiates.

Opium, a

derivative from the seeds of the opium poppy, has been eaten

and smoked for centuries (Carlson, 1992, p. 131).

Morphine,

one of the naturally occurring ingredients of opium, is used

as a pain killer and it possesses highly addictive properties
(Pinel., 1993, pp. 438-439).

Heroin, also known as

diamorphine, is the most commonly abused opiate and,

curiously, its centrally active component is morphine (Di
Chiara & North, 1992).

The effect most valued by opiate

addicts is the rush that follows intravenous injection
(Snyder, , 1980).

Ths heroin rush has been described as a wave

of intense, abdominal, orgasmic pleasure that evolves into a
state of calmness, and drowsy euphoria (Snyder, 1980).

,

Much of our understanding about drug abuse is based on

the observations that drugs possess the ability to act as

reinforcing stimuli (Wise, Bauco, Carlezon & Trojniar, 1992).
A great deal of research is currently being done to
understarid and determine the neural substrates that mediate

the reinforcing or rewarding actions of psychomotor

stimulants and opiate drugs.

More specifically, current

research has focused on the anatomical, neurochemical and

developmental differences involved in reward mechanisms.

In

general, research findings in these areas indicate that

dopamine (DA) is intimately associated with the rewarding
effects of psychomotor stimulants and opiates (McDougall,
Nonneman, & Crawford, 1991/ Phillips, 1984/ Wise, 1980/ Wise

& Rompr§, 1989).

Like many abused drugs, opiates activate dopamine
neurons, albeit indirectly, and affect behavior (see Di

Ghiara & North, 1992, for review).

For example, systemic

injections of opiates increase feeding and lever-pressing for
brain stimulation (Broekkamp et al., 1976/ Mellb, Meldenson,
& Bree, 1981/ Morley & Levine, 1981).

Also, animals, when

given a choice, will self-administer opiates intravenously,
and prefer the particular location where they previously
received the drug.

Moreover, these opiate-induced behaviors

are blocked by dopamine antagonists such as haloperidol and

the opiate receptor antagonist naloxone (Bozarth, 1987a/
Bozarth & Wise, 1981/ Koob, 1992).

The latter results

indicate again that the reinforcing properties of opiate

drugs are ultimately mediated through both opiate and

dopamine pathways.

Curiously, the kappa agonist U50,488 also

blocks reward processes, presumably by depressing dopamine

functioning (Crawford, McDougall, Bolahos, Hall, & Berger, in
press).

The majority of studies assessing the pharmacology of
reward have been tested in mature organisms.

However,

age-dependent differences in dopamine-mediated behaviors have

been reported (Bolanos, Duke, McDougall, & Crawford, 1994;

McDougall & Bolanos, 1995; McDougall, Crawford, & Nonneman,
1992a; Moody & Spear, 1992).

Therefore, the purposes of this

study are: a) to pharmacologically assess the developmental

differences of morphine-induced reward as measured by the
conditioned place preference paradigm (CPP); b) to assess the
ability of the kappa opioid agonist U50,488, to block

morphine-induced reward; and c) to identify the brain areas

activated by thess drugs using Fos immunocytochemistry.
REWARD PATHWAYS.

The Law of Effect initially proposed by Edward Lee

Thorndike states that reward and punishment play a central

role in shaping behavior by increasing or decreasing the
probability for a particular behavior to occur in the future

(Domjan & Burkhard, 1993, p. 125).

For example, an event

that increases the likelihood for a behavior to occur again

is called a reinforcer, whether this reinforcer is positive
or negative.

A positive reinforcer is a stimulus that

increases behavior upon its presentation.

Positive

reinforcers are normally associated with positive affect ,
(mood) and are usually referred to as rewards (Rovee & Rovee,

1969).

A negative reinforcer is a stimulus that upon

"omission" produces an increase in behavior.

An example of

negative, reinforcer is the omission of an electric shock when

a laboratory rat presses a lever.

In this case, the rat will

repeatedly press a lever to stop the electric shock (Domjan &
Burkhard, 1993, p. 138).

Reward Svsterns: Neuroanatomica 1

Studies

,

The discovery of the positive reinforcing effects of
electrical self-stimulation of the brain led to the

conclusion that reward could occur as a consequence of brain
stimulation and that reward could also be studied
physiologically. (Olds & Milner, 1954) .,

In the search for the

neuronal substrates of reward, several paradigms have been

developed.

Among others, neuroanatomical, pharmacological,

and neurochemical techniques have been widely used.

The

neuroanatomical method is based on extensive mapping of the
brain.

In 1954, Olds and Milner found that electrical

Stimulation of discrete brain regions (intracranial self-

stimulation; ICSS) could reinforce different types of

behavior in the rat.

Since this discovery, many attempts

have been made to determine the different brain areas that

mediate reward, and to place them under a unified
neuroanatomical model of reward (Olds & Milner, 1954; Olds &
Olds, 1963).

The first neuroanatomical studies indicated that the

reinforcing effects of brain stimulation were mediated by,the
medial forebrain bundle (Olds & Olds, 1963; 1969).

The

medial forebrain bundle is a large tract of mixed, long and
short, ascending fibers of various types: DA, NE

(norepinephrine), ACh (acetylcholine), and 5-HT (serotonin).

This bundle passes through the lateral hypothalamus, and its
ascending and descending axons interconnect forebrain and

midbrain areas.

DA fibers from the VTA also travel through

the medial forebrain bundle and innervate discrete brain

areas, such as the nucleus accumbens, prefrontal cortex and

neostriatum.

This DA pathway is known as the mesolimbic

mesocortical pathway (Pinel, 1993, p. 448; Wise & Bozarth,
1984; Wise & Rompre, 1989).

In recent years, new findings have suggested that the

multiple brain sites mediating ICSS may not be interconnected

under a single anatomical brain reward substrate (Phillips,
1984).

For example, animals show high rates of ICSS even

after damage to the entire medial forebrain bundle (Corbett,

Lafferi^re, & Milner, 1982). Also, substantial damage to the
mesolimbic DA system does not diminish "normal" self

stimulation at the lateral hypothalamic level (Stellar,
Illes,

Mills, 1982/ Wise & Rompre, 1989).

Furthermore, PET

scan studies indicate that intracranial stimulation applied
to other brain areas that also mediate reward do not activate

the medial forebrain bundle.

For example, electrical

stimulation to the medial prefrontal cortex and the locus

coeruleus do not activate the medial forebrain bundle,
indicating that stimulation to these brain areas is not

mediated by the same neuronal circuit (Gallistel, Gomita,

Yadin, & Campbell, 1985; Robertson, 1989; Yadin, Guarini, &
Gallistel, 1983).

Despite the different substrates that mediate ICSS,
electrical stimulation to the medial forebrain bundle

produces the highest rate of responding (Koob, 1992).

Also,

the period of training necessary to obtain these high and
stable rates are much shorter for the medial forebrain bundle

than for other brain areas.

Thus, these results indicate

again that the medial forebrain bundle may be the critical

anatomical pathway in mediating reward (Crow, 1972; German &
Bowden, 1974; Koob, 1992; Olds & Fobes, 1981; Robertson,
1989; Wise & Rompre,, 1989).

Pharmacological Studies: Rola nf da in Reward

Pharmacological studies have demonstrated that DA plays
an important role in mediating reward (Bozarth, 1987b; Le

Moal & Simon, 1991; Wise, 1978; Wise & Rompre, 1989).

Indirect dopamine agonists such as cocaine and amphetamine
are highly reinforcing and readily self-administered,(Wise,
1988).

For example, cocaine and amphetamine increase bar

pressing for ICSS and drug self-administration into the

medial prefrontal cortex and nucleus accumbens (Goeders &

Smith, 1986; Hadfield & Nugent, 1983; Hoebel et al., 1983;
Pettit & Justice, 1991).

Support for this notion comes from

studies showing that nonselective DA antagonists [i.e.,
pimozide and (+)-butaclamol] decrease the rate of intravenous

d-amphetamine self-administration (Yokel & .Wise, 1976).
Furthermore, ,6-hydroxydopamine (6-OHDA) lesions of the

ascending DA fibers of the mesolimbic-mesocortical pathway
attenuate ICSS in the VTA (Fibiger, LePiane, Jakubovic, &
Phillips, 1987), and 6-OHDA lesions of the nucleus accumbens
produce a long lasting attenuation of cocaine self-

administration (Roberts, Koob, Klonoff, & Fibiger, 1980).
Numerous studies on DA receptor subtypes have implicated
DA Di and D2 receptors in reward (Nakajima, 1989).

For

example, blockade of Di receptors with SCH 23390 reduces

operant responding for brain stimulation, food, and water in

adult rats' (Kurumiya & Nakajima, 1988; Nakajima, 1986;
Nakajima & McKenzie, 1986).

Similarly, SCH 23390 attenuates

the rewarding effects of nipple attachment in rat pups

(McDougall et al., 1991; McDougall, Crawford, & Nonneman,

1992b).

Other studies have reported that DA antagonists,

with a high affinity to the D2 receptor, attenuate ICSS and
operant responding for food (Gallistel & Davis, 1983/

Nakajima & Baker, 1989).

Thus, both Di and D2 receptors

appear to be necessary for the full manifestation of reward

(Clark & White, 1987; Koechling, Colle, & Wise, 1988),

In

agreement with this, combined treatment with Di and D2
antagonists produces maximal attenuation of reinforced

responding.

For example, a SCH 23390-induced decline in

deprivation-induced feeding is potentiated by sulpiride (a D2
antagonist) in the adult rat (Koechling et al., 1988).

Similarly, sulpiride potentiates the reward depressing
effects of SCH 23390 in the preweanling rat fMcDougall et
al., 1991, 1992b).

Weurochemical Studies: Fluorescent Histochemistrv and Fog

Immunocvtochemistry

Brain mapping studies have demonstrated that DA fibers

are involved in brain stimulation, since many reward sites
are closely situated to dopaminergic pathways (Clavier &

Corcoran, 1976; Corbett & Wise, 1980).

For example, Corbett

and Wise (1980) used movable stimulating electrodes, in

combination with fluorescence histochemistry, to map the
midbrain and the caudal diencephalon for ICSS.

The electro-

histochemical data suggest that sites which supported ICSS

were restricted to areas where layers of DA cell bodies were
present.

Neuroanatomical (ICSS and lesion studies) and

pharmacological studies have been successful in identifying
the different nuclei involved in reward.

However, electrode

implantation or lesions to discrete brain areas are likely to
activate or damage several components of the DA system (Le
Moal & Simon, 1991/ Wise & Rompre 1989).

Thus, researchers

have recently started to neurochemically identify the
substrates involved in reward, the specific neurons within
these nuclei, and the neurochemicals within these neurons

(Watson, Trujillo, Herman, & Akil, 1989).

A number of studies have demonstrated that a series of

changes in a cell's gene transcription take place due to the
Cell's responses to stimuli such as stress or psychoactive
drugs (Dragunow & Robertson, 1990; Graybiel, Moratalla, &
Robertson, 1990). Therefore, an approach used to identify
these metabolically active neurons is Fos

immunocytochemistry. Fos, the product of the early response
gene c-fosh is transiently expressed in response to a variety
of physiological and pharmacological stimuli and can be used
as a marker for neuronal activation in the CNS (Miller, 1990;

Sagar, Sharp, & Curran, 1988).

Neurotransmitter regulation

of gene expression is known to occur via a, second messengerdependent induction of a class of proteins, referred to as

transcription factors or proto-oncogenes (Montminy, Gonzalez,
& Yamamoto, 1990).

Many of these proto-oncogenes have been

identified, including c-fos, c-jun, GREB, and several others.
Because of their position between cellular events (between
second messenger and gene ,transcription) they are also called

"third messengers'V (Sagar et al., 1988) ..

One of,the most widely studied of these factors is the

proto-oncogene c-fos.

C-fos is activated by a variety of

different processes that influence cellular activity.
Recently, a number of studies have demonstrated that

activation of the mesostriatal and mesolimbic DA system

induces Fos-like immunoreactivity.

For example, neuroleptics

such as haloperidol and clozapine increase c-fos expression
in rat forebrain structures (Robertson & Fibiger, 1992).

It

has also been demonstrated that the amphetamine-stimulated

release of dopamine, as well as the direct activation of DA Di
receptors, produces c-fos induction in rat mesolimbic and

mesostriatal DA terminals (Dilts, Helton, & McGinty, 1993;
Robertson, Peterson, Murphy, & Robertson, :1989).

Furthermore, the ability of cocaine and amphetamine to induce

Fos is blocked by SCH 23390 (Graybiel et al., 1990; Young,

Porrino, & ladarola, 1991).

More recently, our laboratory

demonstrated that the kappa agonist U-50,488 blocked cocaine-

induced "Fos activity in adult rats (Crawford et al., in
press).

These results indicate that pharmacological
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manipulation can induce or block Fos activity/ and Fos, in
turn, can be used to identify the neurons and circuits

involved in the actions of drugs.
In summary, neuroanatomical, pharmacological and
immunocytochemical studies have contributed to the

identification of the neuronal circuits that mediate drug
reward.

Psychopharmacological.studies, in particular, have

been important for determining the role of DA in mediating
the positive reinforcing properties of drugs (Bozarth,

1987b).

Even though the existence of separate reward systems

has been suggested (see Phillips, 1984, for a review),

overwhelming evidence supports the existence of a general
reward DA pathway '(Watson et al., 1989; Wise & Bozarth,
1987).

This reward pathway also known as the mesolimbic

mesocortical pathway consists of: (1) descending fibers in
the medial forebrain bundle connecting the lateral

hypothalamus and the VTA, (2) opioid.peptide-containing
fibers that terminate in the ventral tegmental area, (3)
dopaminergic cells projecting from the VTA to the nucleus
accumbens, and (4) dopaminoceptive cells of nucleus accumbens

which carry the reward signal from these inputs to other

undetermined areas (Watson et al., 1989; Wise & BOzarth,

1984).

Therefore, because of its implication for reward, one

of the purposes of this study is to determine those brain
areas activated by opiate-acting drugs.
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To that end, Fos

activity will be assessed across brain.

It is predicted that

pronounced activity will be apparent in those brain areas

that make up the mesolimbic-mesocortical pathway.

OPIATE RECEPTORS AND REWARD

Qpiate -Receptorsi Location. Classificdtiony and Thei n Profiles
of Action

:0

opioid neurotransmitters have been

observed in brain areas (liitbic and forebrain structures)

that re

mood states.

Briefly,

ehkephalins, a type Of endog^hous opiate/ are natural

occurrihg peptidds which bind^^ t

opiate receptors (Hong,

Yang, Fratta, & Costa, 1977; La Motte, Snowman, Pert, &
Snyder, 1978).

Opiate receptors have been classified into

three ittajbr subtypes: mu> delta/ and kappa (Lord/ Waterfield/
Hughes, & Kosterlitz, 1977).

: have reyedled that

Ligand-receptor binding studies

possesses high affihity fdr liiu: (}i)

receptors (Brady, Herkenham, Long, & Rothman, 1989).

Delta

(5) receptors are activated by enkephalin, whereas kappa (K)
receptors are activated by deltrophins (Erspamer et al.,
1989; Wagner, Evans, & Chavkin, 1991).

Different profiles of action have been described for mu,
delta, and kappa receptors.

Mu receptors are associated with

the positive reinforcing effects of opiates.

For example, mu

agonists (e.g., morphine) lower the electric current'
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threshold for ICSS, indicating that morphine-like opiates
directly activate reward processes (for reviews see'Di Chiara
& North, 1992, and Koob, 1992).

Additionally, morphine and

heroin are readily self-administered in the nucleus accumbens

and the VTA (Broekkamp, Phillips, & Cools, 1979; Jenck,

Gratton, & Wise, 1987; Olds, 1982).

Delta receptors,

although less extensively studied, have also been implicated
in reward.

For example, delta opiate agonists (e.g., DPDPE)

induce place preference conditioning, increase locomotor
activity, and induce feeding in satiated rats (Koob, 1992;
Shippenberg, Bals-Kubik, & Herz, 1987).

While mu and delta agonists function as positive
reinforcers, kappa receptor agonists induce aversive states.
For example, kappa agonists (ethylketazocine and tifluadom)

induce taste aversion, and U-50,488, a highly selective kappa
agonist induces both taste and place aversions (Bals-Kubik,
Herz, & Shippenberg, 1989; Bechara & van der Kooy, 1987;
Mucha & Herz, 1985).

Recently, it has been demonstrated that

kappa agonists also modulate DA neurotransmission.

For

example, U-50,488 blocks morphine-induced DA turnover in both

the mesolimbic and nigrostriatal DA system (Di Chiara &

Imperato, 1987; Narita, Suzuki, Funada, Misawa, & Nagase,
1993).

In agreement with these findings, Di Chiara and

Imperato (1987) found that kappa agonists reduce DA release

in the nucleus accumbens and nigrostriatum of freely moving
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rats, while at the same time, reducing locomotor activity.
when taken together, these findings indicate that

opioid receptors modulate DA functioning: mu and delta

agonists stimulate, while kappa agonists inhibit DA activity
in brain areas associated with reward.

Role Of DA Neurons in Opiate hew^^^rd'

A close association between enkephalin containing fibers

and dopaminergic neurons has been established. For example,

concentrations.of enkephalin and large numbers of opiate
receptors are found in brain areas (e.g., the nucleus

accumbens and the VTA) containing DA neurons (Johnson, Sar, &
Stump, 1981; Mansour, Khachaturian, Lewis, Akil, & Watson,
1988; Waksman, Hamel, Delay-Goyet, & Rogues, 1986).
Intracranial injections of opiates into the VTA, an area
containing dopaminergic cell bodies labeled AlO, are
reinforcing (Watson et al., 1989). Consistsnt with these

f^iridings, electrophysiological evidence demonstrates that
application of morphine directly on AlO DA neurons causes a

pronounced membrane depolarization (Matthews & German, 1984).

In .addition, , both naloxone (an opiate receptor antagonist)
and pimozide (a dopamine receptor antagonist) block heroin's
rewarding effects, suggesting that opiate—mediated reward is

dependent on a dopaminergic substrate (Bozarth & Wise, 1981).

Thus, several lines of evidence suggest that the rewarding
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effects of opiates (i.e., morphine and heroin) are also
mediated by a central DA mechanism.

Like psychomotor stimulants (e.g., cocaine and

amphetamine), opiates have the ability to produce positive

reinforcing effects when injected into the nucleus accumbens,
VTA, lateral hypothalamus-and hippocampus (Bozarth, 1987b;
Broekkamp et al., 1979; Corrigal & Linseman, 1988; Olds,

1982; Watson et al., 1989).

These areas are apparently

interconnected, as activation of opioid receptors in the VTA
causes the release of DA in the nucleus accumbens, medial

prefrohtal cortex, and lateral hypothalamus (Watson et al.,
1989; White, 1989).

Consistent with this notion, it has been

demonstrated that intracranial injections of the Di receptor
antagonist SCH 23390 into the nucleus accumbens attenuates

the rewarding effects of ICSS in the VTA (Kurumiya &
Nakajima, 1988).

Similarly, lesions of DA neurons in the

nucleus accumbens blocks cocaine, heroin, and morphine self-

administration, again showing that the nucleus accumbens play
a critical role in modulating opioid and DA reward (Dworkin,
Guerin, Goeders, & Smith 1988; Koob, Stinus, Le Moal, &
Bloom, 1989; Wise & Rompre 1989).
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Conditionet^ PXace Preference (CPP): DA-Opiate interaction
Although the different paradigms reviewed thus far

(e.g., ICSS, drug self-administration, etc.) have provided
important information on the neural substrates that mediate

reward, these procedures have some limitations.. For example,

in these paradigms, animals are-usually required to- perform
complex motor responses under the influence of neurochemicals

that may impair their sensorimotor processes (Ettenberg,
Koob, & Bloom, 1981),

An approach that seems to avoid this

potential confound is the conditioned place preference (CPP)

paradigm.

In this paradigm, a drug is paired with a specific

environment and saline is paired with an alternative

environment.

After conditioning, animals are tested in a

drug-free state in which they have free access to both

environments simultaneously. Place preference conditioning
is apparent when the animal spends a significantly greater
percentage of time in the drug-paired environment.

Traditionally, odor, tactile and visual stimuli are used to

distinguish the environments of the CPP apparatus.
A number of different reinforcers have been used to

produce CPP. For example, CPP is produced by, injecting
amphetamine either systemically or directly into the ventral

tegmental area.

Also, cocaine induces a robust CPP (Bardo,

Neisewander, & Miller, 1986; Carr & White, 1983/ Trujillo,
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Belluzzi, & Stein, 1991).

The reinforcing effects induced by

cocaine and amphetamine are blocked by lesions to the

prefrental cortex, lesions of the nucleus accumbens and by

high doses of the D2 antagonist haloperidol (Isaac, Nonneman,
Neisewander, Landers, & Bardo, 1989; Spyraki, Fibiger, &
Phillips, 1983).

However, others have reported that neither

6-OHDA lesions nor DA receptor blockers disrupt cocaine-

induced CPP (Morency & Beninger, 1986/ Spyraki, Fibiger, &
Phillips, 1982; Spyraki, Nomikos, & Varonos, 1987).
Interestingly, amphetamine- and cocaine-induced CPP is

blocked by opioid antagonists such as naloxone (Bilsky,
Montegut, Belong, & Reid, 1992; Trujillo et al., 1991).

in

addition, the ICSS threshold-lowering effect of cocaine are
antagonized with naloxone (Bain & Kornetsky, 1986).
Furthermore, the mu receptor antagonists naltrexone and
buprenorphine reduce cocaine self-administration in non-human

primates and humans (Mello, Mendelson, Bree, & Lukas, 1989,
1990; Trujillo et al., 1991).

To further delineate the interaction between DA and

opiates in reward, it has been demonstrated that pretreatment.
with DA.antagonists attenuates the appetitive effects induced
by heroin and morphine (Bozarth, 1987a, 1987b; Bozarth &

Wise, 1981; Phillips & LePiane, 1980; Shippenberg & Herz,
1987; Watson et al., 1989).

For example, haloperidol blocks

CPP produced by systemic injections of morphine and by
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microinjectiohs of morphine into the VTA (Bilsky, Marglin, &
Reid, 1990; Phillips & LePiane, 1980; Schwartz & Marchok,
1974; van der Kooy, Mucha, 0'Shaughnessy, & Bucenieks, 1982)
Pretreatment with DA antagonists, as well as lesions to the

VTA, disrupts the rewarding effects of heroin self-

administration and heroin-induced CPP (Bozarth & Wise, 1981;

Spyraki et al., 1983).

Furthermore, the DA antagonist SCH

23390 attenuates morphine-induced CPP (Leone & Di Chiara,
1987; Shippenberg & Herz, 1987).

However, despite

overwhelming evidence implicating a central DA mechanism in .

mediating opiate-reinforcing properties, other researchers

have reported that neuroleptics, such as haloperidol and a

flupentixol, do not attenuate the rewarding effects of
morphine-induced CPP nor heroin self-administration

(Ettenberg, Pettit, Bloom, & Koob, 1982; Mackey & van der
Kooy, 1985).

Although the interaction between the mu opioid and DA

systems is understood, the interactions between the kappa
opioid and DA system are less well delineated.

However,

interactions do exist, as our laboratory has recently
demonstrated that the kappa agonist U-50,488 attenuates a

variety of cocaine-induced behaviors.

For example, U-50,488

attenuates cocaine—induced locomotor activity and blocks

cocaine-induced reward (Crawford et al., in press).
Interestingly, these findings indicate that kappa neurons
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modulate those DA systems involved in both reward and

unlearned behavior.

The mechanisms by which kappa agonists

depress behavior are unclear; however, the ability of kappa
agonists to reduce DA release in the nucleus accumbens and.

striatum may provide the basis for U-50,,488's dopamiiiergic

actions (Crawford et al.., in press; Di Chiara & Imperato,
1987; Werling, Fattali, Portoghese, Takemori, & Cox, 1988).
In summary, the data seem to leave little doubt'that

dopamine is important for mediating the rewarding properties

of both psychomotbr stimulants and opiate drugs (Bozarth &
Wise, 1981; Watson et al., 1989). Specifically, these data

indicate that: 1) DA neurons mediate opiate-induced reward,
2) DA antagonists are able to block these rewarding effects,
3) DA receptors in both the VTA and the nucleus accumbens are

important for the reinforcing actions of psychomotor

stimulants and opiate drugs, 4) kappa agonists (e.g., U

50,488) attenuate DA mediated behaviors, perhaps by
decreasing- DA release into the nucleus accumbens, and 5)
direct DA antagonist treatment in the nucleus accumbens
attenuates the rewarding effects of psychomotor stimulants

and opiates microinjected or self-administered into the VTA.

These data also indicate that the CPP paradigm is'able to

assess the rewarding properties of psychoactive drugs, and,
unlike paradigms that involve operant responding, CPP

19

dissociates motor performance from reward (Crawford et al.,

in press; Hoffman, 1989; Koob et al., 1989).

ONTOGENY OF REWARD

Behavioral and Developmental Differences in Response to Drugs
, "

Analysis of brain function at the ontogenetic level has

produced important findings that have contributed to the
understanding of the organism as a whole.

It has been

established that developing organisms often respond
differently to psychopharmacological challenge than adult
organisms (see Spear, 1979, for a review).

For example, in

adult rats pretreatment with the irreversible DA antagonist
EEDQ attenuates the behavioral effects induced by NPA (a DA
agonist).

In contrast, EEDQ does not attenuate the NPA-

induced behaviors in 11- and 17-day-old rat pups (McDougall &
Bolanos, 1995; McDougall et al., :1992a; Mestlin & McDougall,
1993).

Rat pups also respond differently to psychomotor

stimulants when compared to adult rats.

For example, when

given cocaine between 7 and 2T days of age, rat pups show
more locomotor responding than adult rats.

At 28 days of

age, rats respond to cocaine in an adult typical manner
(Spear :& Brick, 1979).

Ontogenetic differences have also been observed in

animals treated with morphine.

For example, Gaza and Spear

(1980) reported that at lO-day'^.old rats given low :(0.5, or
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1.0 mg/kg) or high (5.0 mg/kg) doses of morphine showed a
decrease in locomotor activity.

Interestingly, 17-day-old

pups.given a low dose (0.5 mg/kg) of morphine showed an

increase in locomotion, whereas a high dose (5.0 mg/kg)
decreased loGomotor activity (Caza & Spear, 1980).

These

findings;are interesting, since adult■rats show an increase

in locomotor activity at low doses (1.0 mg/kg) and-a decrease
in locomotion at high doses (5.0 mg/kg) of morphine (Ayhan &
Randrup, 1973/ Fog, 1970) .

Ontoaenv of Reward and Receptor Development

Although less extensively investigated, reward processes
have been studied in young animals (Smith & Holman, 1987) .
For example, electrical self-stimulation occurs in 3- and 10

day-old rat pups in the same brain areas (i.e., nucleus
accumbens, lateral hypothalamus, olfactory tubercle and

medial forebrain bundle) as those found to be reinforcing in
adult rats (Barr & Lithgow, 1986; Moran, Lew, & Blass, 1981,
1983) .

Similarly, systemic and intracerebroventricular

injections of morphine induce CPP in rat pups (Barr & Rossi,
1992; Kehoe & Blass, 1986b) .

Thus, these findings indicate

that the biological mechanisms that mediate reward are

present in the neonate and appear to be similar to the neural
substrates that mediate reward in the adult.
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In the case of opiate receptors/ it has been

demonstrated that mu and kappa binding sites are present

before birth, and that delta binding sites emerge postnatally
(Spain, Roth, & Coscia, 1985).

Consistent with this,

neurochemical studies have determined that mu and kappa
receptors appear to be functional in the rat at 17 days of

gestation, and delta receptors as early as 7 days postnatally
(DeVries, Hogenboom, Mulder, &•Schoffelmeer, 1990).

These

findings are generally consistent with ontogenetic behavioral
data.

For example, Jackson and Kitchen (1989) reported that

mu agonists (e.g., morphine and DAGO) produce behavioral

inhibition in 5-, 10- and 20-day-old rats, while kappa
agonists (e.g., U50,488 and PD117,302) produce hyperactivity
with increased wall-climbing at 5- and 10-days of age.

In

contrast, the delta agonist DPDPE did not exert any
behavioral effects at any of the ages tested (Jackson &
Kitchen, 1989).

Periadolescence

A stage of development that has been relatively

understudied is periadolescence (approximately 28 to 40 days
of age). Periadolescerit animals are hyperactive and appear
to engage in more playful behavior than preweanling or adult
rats (see Spear & Brake, 1983, for review).

Periadolescent

rats also show different behavioral responses when challenged
by■psychoactive drugs.

For example, when given amphetamine,
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18-dayT-old rats show adult-like behaviors, while 35-day-olds
failed to show the same adult-like responses (Infurna &
Spear, 1979).

Also, periadolescents are less sensitive to

cocaine and apomorphine, tend to perform poorly on complex

learning tasks, but perform quite well on simpler learning
tasks (Shalaby & Spear, 1980; Spear & Brake, 1983; Spear ,&
Brick, 1979). Furthermore, low doses of morphine (1 and 2

mg/kg) increase locomotor activity in adult anim-als (Ayhan &
Randrup, 1973); however, the same doses of morphine

accentuate locomotor activity in periadolescents (Spear,

Horowitz, & Lipovsky, 1982). In agreement with this,
Laviola, Dell'Omo, Alleva and Bignami (1992) reported that

low doses of cocaine (e.g., 5 mg/kg) induced CPP in 21-day
old rats, while the same dose failed to induce CPP in
periadolescents (31-day-olds).
In summary, analyses of-the development of brain

function have contributed to the understanding of the mature

organism. Brain substrates that mediate the rewarding
effects of electrical stimulation are functional in rats as

young as 3 days of age (Barr & Lithgow, 1986; Moran et al.,
1981). . Additionally, 7-day-old pups prefer the odor and the

environment where they received intraoral milk reinforcement

1990). Thus, the brain areas that mediate rewarding

and appetitive behavior appear to develop, at an early age.
Although-relatively understudied, research using
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periadolescents has provided interesting results.

Periadolescent rats appear hyperactive, they perform poorly
in complex learning tasks and respond differently than young
and adult animals when challenged- with cocaine, amphetamine
or morphine (Infurna & Spear, 1979; Shalaby & Spear, 1980;
Spear & Brick, 1979; Spear et al., 1982).

Thus, another

purpose of the current study is to compare CPP in both
preweanling and periadolescent rats.

SUMMARY

The discovery of intracranial self-stimulation by Olds
and Milner- (1954) facilitated the localization of those brain

areas that mediate reward.

Although, the possibility of

multiple reward systems cannot be discounted (see Phillips,
1984, for review), overwhelming evidence suggests that the DA
system is the primary neurosubstrate responsible for reward
(Wise & Rompre, 1989).

Ontogenetic research has demonstrated

that brain areas which support reward in adult organisms also

mediate reward in the young animal (Laviola et al.,. 1992;
Moran et al., 1981; Spear, 1982), however some age dependent

differences in reward mechanisms have been reported.

For

example, McDougall and colleagues (1991, 1992b) have

demonstrated that sulpiride, a D2 antagonist, potentiates the
reward depressing effects of the Di antagonist SCH 23390 in
11- and 17-day-old pups: an effect not consistent with adult
studies.

Additionally,, periadolescent rats show behavior
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patterns which are inconsistent with both adult and

preweanling rats (Ayhan & Randrup, 1973/ Caza & Spear, 1980;

Fog, 1970; Laviola et al., 1992; Spear & Brake, 1983).
General Purpose and Hypotheses

Although the advantages of ontogenetic research have

been established, the majority of neurobehavioral studies

have been done using adult organisms (Spear, 1990).

Thus,

this ontogenetic study took advantage of the immaturity of
the opioid system in the young rat to further assess the

neuropharmacology of reward.

More specifically, this study

attempted to determine: a) the morphine-induced behaviors of

periadolescent and preweanling rats, b) whether the kappa
agonist U-50,488 can block the conditioned bahavior (CPP) of

various aged rats, and c) those neuroanatomical pathways
which exhibit Eos activity in response to place preference
conditioning.

It was predicted that: 1) morphine would

induce CPP in 10- and 17-day-old rats but .fail to induce CPP

in the 35-day-old rat, 2) the kappa agonist U-50,488 would

block morphine-induced CPP, and 3) Eos activity would be

enhanced by morphine-induced CPP and blocked by U-50,488
pretreatment.
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EXPERIMENT 1

In studies using operand responding (e.g., selfadministration of drugs) to assess reward, animals are
required to perform motor re^sponses under the influence of

neurochemicals that may impair their sensorimotor processes
(Ettenberg et al., 1981).

An approach that seems to avoid

these potential, confounds is the CPP,paradigm in which
animals' are tested in a drug-free state. (Hoffman, 1989).
When assessing drug—induced behaviors in young animals,

ongoing maturational changes can be a confounding variable.
Thus, an abbreviated CPP procedure is preferable (Laviola et

al., 1992/ Spear, 1990).

Recently, Pruitt, Bolanos, and

McDougall (in press) have shown that a 3 day procedure is

sufficient'to establish a cocaine-induced CPP in preweanling
rats.

Thus, in the present experiment, an abbreviated CPP

procedure (3 days) was used to assess morphine's ability to
induce CPP in 17-day-o.ld rats.
Method

Subjgets•.

Subjects were 32 male and female rats of

Sprague-Dawley descent (Harlan), born and raised at

California State University, San Bernardino.
tested at 17 days of age.

Rats were

Litters were culled to a maximum

of ten or a minimum of eight pups at 3 days of age. Rat pups
were kept with the dam throughout behavioral testing.
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Assignment of subjects was random with no more than one rat

from each-litter placed into a particular testing group.

The

colony room was maintained at 23-25° C and kept under a 12:12

light:dark cycle.
phase of the cycle.

Testing was conducted during the light
A protocol for the procedure was

approved by the Animal Care Committee.

The testing apparatus was a rectangular plywood chamber that

had three compartments separated by removable partitions.

The end compartments measured 15.5 x 15.5 x 21.5 cm high,
while the middle compartment measured 9 x 15.5 x 21.5 cm

high. All compartments were painted gray and were covered by
a clear Plexiglas top.

One end compartment had smooth

plywood flooring; whereas the other end compartment had

plywood flooring scored (2 dm deep) in a checkerboard
fashion.

Besides the tactile differences, both end

compartments were eguipped with an odor delivery system.
More specifically, beneath each end compartment, and

connected via 15 small holes in the floor, were rectangular

containers (4.5 cm deep) that were paftially filled with pine
wood chip bedding.

Lemon and almond extract were applied to

the pinewood bedding of each container to provide distinctive
odor cues for the end compartments (10 cc of the extract were

used for conditioning and 1-cc was used for preference
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testing).

Lemon and almond odors were purchased from

commerciai vendors (Irish, Inc).• During conditioning, solid
partitions were used to keep rats in the appropriate
compartments; whereas, during testing, the partitions were

raised- 5.5 cm, so that each rat could move freely between the
compartments.

Procedure and Drugs

In each, experiment there were two conditioning days

followed by a. test day. .On the conditioning days, two 30-min
conditioning sessions were presented 4 hr apart.

On the

first day of conditioning, rats were given saline only and
were placed in a chamber scented with 10 cc of almond or

lemon extract.

On the second conditioning day, rats received

morphine (0.1, 0.2, or 0.5 mg/kg) or saline (i.p.) and were
placed in the opposite chamber scented with 10 cc of almond
or lemon extract.

conditioning days.

The scents were counterbalanced across

Morphine sulfate (Research Biochemicals

Inc., Natick, MA, USA) was dissolved in distilled water and

was injected intraperitoneally (i.p.) at a volume of 5.0

ml/kg.

On the. testing day, rats were given saline and had

free access to all chambers for 15 min.

Both conditioning and tes.t trials were videotaped for
scoring at a later date by experimenters blind to the
treatment conditions.

During conditioning,. the data recorded
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included: locomotor activity (line-crossings), rearing, and
wall climbing.

On the test day the data included: percent

and total time spent in the drug-paired chamber (CPP),
locomotor activity, rearing, and wall climbing.

CPP was

defined as a rat. spending significantly more time in the
morphine-paired (lemon or almond) chamber.

Locomotor.

activity (line-crosses), rearing, and wall climbing were
measured continuously, with line-crosses being defined as a

rat putting both forepaws and snout into an adjacent quadrant
in the CPP chamber.

Statistical Analyses .
were used to assess CPP.

Analyses of variance (ANOVAs)

Locomotor activity (line-crosses),

wall climbing, and rearing were analyzed using ANOVAs.

Significant main effects were further analyzed using Tukey
tests, (p. < .05).

Analyses of wall climbing and rearing did

not reveal significant effects, so that data is not
presented.

riesults

Locomotor Activitv Purina Conditioning .

Mean locomotor

activity counts of morphine-treated rat pups are shown in

Figure 1.

On the conditioning day, the locomotor activity

(line-crosses) of pups receiving morphine (0.1, 0.2, or 0.5

mg/kg) did not differ from saline-treated rat pups.
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Conditioned Place. PrPiffirf^riQf^ . , The percent time and

total, time spent by 17-day--old rats, in the : drug-paired
compartment can-be seen in Figures ,2 and 3,

Rats treated

with 0.5 mg/kg morphine spent.a significantly, greater
percentage of time in the drug-paired compartment than did

their saline controls, E (3,28) ,= 2.44, p < .05, and Tukey
tests (p < .05). Similarly, rats given 0.5 mg/kg morphine
spent more total time in the drug-paired compartment than

rats treated with saline, E (3,28)
tests (p < .05).

3.12, p < .05, and Tukey

Rats given lower doses of morphine (0.1 or

0.2 mg/kg) did not differ from their saline-treated controls.
Conditioned Locomotor Activity .

Mean locomotor

activity counts on the testing day are presented in Figure 4.
Previous morphine treatment did not affect .locomotor activity
on the test day.

Thus, these results indicate that morphine

did not induce conditioned hyper or hypoactivity.
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FIGURE CAPTIONS

Mean number (+SEM) of line-crosses in the drug-

paired compartment of the GPP apparatus during both

conditioning sessions (30 min each). The 17-day-old rat pups
were injected with morphine (0.1, 0.2 and 0.5 mg/kg, i.p.) or
saline immediately prior to conditioning (n = 8).

Ei-gure 2.

Mean percent time (+SEM) spent in the drug-paired,

chamber of the GPP apparatus on the test day (n = 8).

Rats

were drug-free on the test day and allowed 900 sec access to

the three CQmpartments. The percent score was determined by

dividing the time spent in the drug-paired compartment by the
time spent in both the saline and drug-paired compartment
(drug-paired/saline-paired+drug-paired).

Figure—2..

Mean total time (+SEM) spent in the drug-paired

chamber of the GPP apparatus on the test day (n = 8).

Rats

were drug-free on the test day and allowed 900 sec access to
the three compartments.. ..

Eigufe 4• Mean number (+SEM) of line-crosses in the GPP

apparatus on the test day, (ri = 8).

Rats were drug-free on

the test day and allowed 900 sec access to the three
compartments.
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EXPERIMENT,2

In a pilot study; a number of moderate.and high.doses of
morphine (1.0, 2.0, 4.0, and 8.,0 mg/kg) were used to
determine whether this mu opioid agonist could induce CPP in

the preweanling rat.

Results from,that study (data not

reported) indicated that none of these higher doses was

capable of inducing CPP.

The results from Experiment 1

demonstrate that a low dose of morphine (0.5 mg/kg) is

rewarding and capable of inducing.CPP in the 17-day-old rat.
These results are consistent with a number of recent studies

showing.that lower doses of morphine are rewarding to
preweanling rats, while higher doses can be aversive (Kehoe &

Blass, 1985a, 1986b, 1989/ Randall, Kraemer, Dose, Carbary, &
Bardo, 1992).

While mu agonists (e.g. morphine) have been shown to

activate reward processes, kappa receptor agonists induce

a.versive states.

However, the aversive effects induced by:

these drugs are dose-dependent, as several studies have : :,

demonstrated that a moderate dose of U-5.0,488 (4-5 mg/kg) is

without; significant aversive properties (Bals-Kubik et al.,
1989; Bechara & van der Kooy, 1987; Crawford et al., in
press; Mucha & Herz, 1985).

In the infant rat, U-50,488's effects are both dose and

age-dependent.

Low doses of U-50,488 (e.g., 3.0 mg/kg) have
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been shown to produce CPP in 3—day-olds and place aversions

in the 7-day-old rat (Barr, 1993).

Therefore, the purpose of

Experiment 2 was to determine.the dose at which U-50,488
would block morphine-induced .CPP, without inducing aversive
or appetitive states. ,

Method

Subjects.

Subjects were 64 male and female rats tested

at 17 days of age.

Procedure and Drugs .

The procedure was identical to

Experiment 1, with the exception that U-50,488 (2.0, 5.0, or
10.0 mg/kg, s.c.) or saline was given 30 min before

conditioning, while morphine (0.5 mg/kg, i.p.) or saline was

injected immediately prior to conditioning. Both morphine
and U-50,488 were obtained from Research Biochemicals Inc.

(USA) and were given at a volume of 5.0 ml/kg.

Statistical Analyses .

CPP, locomotor activity, wall

climbing, and rearing were analyzed by 2 (agonist) X 4

(antagonist) ANOVAs.

When appropriate, Tukey tests (p < .05)

were used for making post hoc comparisons.

Analyses of wall

climbing and rearing did not reveal significant effects, so
that data is.not presented..
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Locomotor Activity Purina Conditioning ,

.aGtivity

Mean locomotor

U-50,488 and morphine-treatdd;17-day-old

rats are shown in Figiire 5;

Overall,,: rat pups receiving U- ,

5G,488 (2,0, 5.0 or lO,0 mg/kg) had sighificantly rriore
locomotor activity counts than saline-treated rats,

:pretreatment main eftectr E (3,56) =:13.40, p < .001. ?
U-50,488's activating effects were partially blocked by :

morphina, posttreatment main effect, £ (1/56)
:'V001:i^''

'■ ■

12,64, p <
■

r:"

Cohditioned Place Preference ,

The percent time and total

time spent in the drug-paired compartment by morphine-treated

17-day-old rats can be seen in Figures 6 and 7,

Rat pups

treated with 0,5 mg/kg of morphine spent a significantly
greater percentage of time in the drug-paired compartment
than saline-treated pups, L (14) = 2,84, p < ,05,

All doses

of U-50,488 (2,0, 5,0 and 10,0 mg/kg) appeared to block this

morphine-induced effect, as pups given morphine alone spent a
greater percentage of time in the drug-paired compartment
than pups given morphine and U-50,488, Pretreatment x

Posttreatment interaction, £ (3,56) =3,04, p < ,05, and
Tukey tests (p < ,05),

Regardless of U-50,488 dose, rats : :

given U-50,488 and morphine did not differ from rats given
the kappa agonist alone,
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Once again, rats treated with only morphine spent

significantly more total time in the drug-paired chamber than
the saline controls, t. (14) = 2.43, p < .05.

This preference

was apparently blocked by U-50,488, because rats treated with

both U-50,488 and morphine did not differ from the saline

controls.

Overall, rats given 10 mg/kg (U-50,488) spent less

total time in the drug-paired compartment than rats injected

with a lesser dose of the kappa agonist (2.0 or 5.0 mg/kg),
pretreatment main effect, £ (3,56) = 3.22, p < .05, and Tukey
tests (p < .05).

These results suggest that 10 mg/kg of U

50,488 may be aversive.

Neither the agonist main effect or

interaction were statistically significant.
Conditioned Locomotor Activity .

Mean locomotor

activity counts on the test day are presented in Figure 8.
Treatment with U-50,488 or morphine did not affect locomotor

activity on the test day.

Thus, there was no evidence of

U-50,488- or morphine-induced conditioned activity.
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FIGURE CAPTIONS

Figure 5.

Mean number (+SEM) of line-crosses in the drug-

paired compartment of the GPP apparatus during both

conditioning sessions (30 min each).

The I7-day-old pups

were injected with U-50,488 (2 mg/kg, s.c.) or saline 30 min

prior to drug conditioning, and morphine (0.5 mg/kg, i.p.) or
saline immediately prior to conditioning (n = 8),

Figure—

Mean percent time (+SEM) spent in the drug-paired

compaitment of the GPP apparatus on the test day (n = 8).
Rats were drug-free on the test day and allowed 900 sec
access to the three compartments.
determine as in Figure 2. '

Figure 1.

The percent scored was
.

Mean total time (+SEM) spent in the drug-paired

compartment of the GPP apparatus on the test day (n = 8).
Rats were drug-free on the test day and allowed 900 sec
access to the three compartments.

Figure—8.- Mean number (+SEM) of line-crosses in the GPP

apparatus on the test day (n = 8).

Rats were drug-free on

the test day and allowed 900 sec access to the three
compartments.
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EXPERIMENT 3

Ontogenetic research has shown that preweanling rats
often respond differently to psychopharmacological challenge
than adults (see McDougall, Crawford, and Nonneman, 1995/ and

Spear, 1979, for reviews).

Surprisingly, periadolescent rats

(approximately 28 to 40 days of age) exhibit drug-induced
responses which are different from both younger and older

animals (Spear & Brake, 1983).

Therefore, the purpose of the

present experiment was to assess the effects of the kappa
agonist U-5G,488 on the morphine-induced behaviors of 10-,
17- and 35-day-old rats.

Method

Subjects .

Subjects were 96 male and female rats of

Sprague-Dawley descent born and raised at California State

University, San Bernardino.
17, of 35 days of age.

Rats were tested at either 10,

The periadolescent rats were weaned

at 21 days of age and kept in separate cages, away from the
dam in groups of no more than 10 rats per cage.
Apparatus

The testing apparatus for the 10- and 17-day-olds was

the same as used in Experiments 1 and 2.

For the 35-day

olds, the testing apparatus was slightly bigger.

The end

compartments measured 20 X 20 X 28 cm high, while the middle
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compartment measured 12 X 20 X 28 cm high.

During testing,

the partitions were raised 9 cm, so that each rat could move
freely between compartments.

Procedure and Drugs .

The same procedure was used as in

Experiment 2, with the exception that only a single dose of
U-50,488 (2.0 mg/kg) or saline was used.

For the .10- and 17

day-olds, morphine and U-50,488 were injected at a volume of

5.0 ml/kg, whereas 35-day-olds were injected at a volume of
2.0 ml/kg.

Statistical Analyses .

CPP, locomotor activity, wall

climbing and rearing were analyzed by 2 (agonist) X 2
(antagonist) ANOVAs at each age.

Significant main effects

were further analyzed using Tukey tests (p < .05).

Results

10-day-olds

Locomotor Activity During Conditioning .

Mean locomotor

activity counts of U-50,488 and morphine-treated 10-day-old
rats are shown in Figure 9.

Rat pups receiving U-50,488 (2.0

mg/kg) had significantly more locomotor activity counts than

saline-treated controls, pretreatment main effect, £ (1,36) =
91.85, p < .001.

The increase in locomotor activity was

blocked by morphine, since rats pretreated with U-50,488 and

morphine had less activity counts than rats receiving the
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kappa agonist alone, Pretreatment x Posttreatment

interaction, £ (1,36) = 7.23, p <.01, and Tukey tests (p <
.05).

Rearing Purina r-onditi nni ng .

Mean rearing counts of

the 10-day-old rats are presented in Figure 10.

The kappa

agonist affected rearing, as 10-day-olds receiving U-50,488
(2.0 mg/kg) had significantly more rearing counts than

saline-treated rats, -pretreatment main effect, £ (1,36) =

31.56, p < .001.

The U-50,488-induced increase in rearing

was partially blocked by morphine, since rats receiving U
50,488 and morphine had fewer rearing counts than pups
treated with the kappa agonist alone, Pretreatment x

Posttreatment interaction, £ (1,36) = 4.65, p < .05, and
Tukey tests (p < .05).

Wall Climbing Purina Condition-i na . Mean wall climbing
counts are presented in Figure 11.

Overall, rat pups

receiving U-50,488 (2.0 mg/kg) had significantly more wall
climbing counts than saline-treated rats, pretreatment main
effect, £ (1,36) = 31.56, p < .001.

Conditioned Place Preference .

The percent time and

total time spent in the drug-paired compartment by morphinetreated 10-day-old rats can be seen in Figures 12 and 13,
respectively.

Percent time spent in the drug-paired

Cbmpartment was not. significantly affected by morphine or U
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50,488.

Rat pups treated with morphine alone spent

significantly more total time in the drug-paired chamber than

the saline controls, i. (18) = 2.48, p < .05.
induced preference was blocked by U-50,488.

The morphineMore

specifically/ rats receiving both U-50,488 and morphine spent
significantly less time in the drug-paired compartment than
rats receiving morphine alone, Pretreatment x Posttreatment

interaction, E (3,31) - 4.43,

p < .05, and Tukey test (p <

.05).

Conditioned Locomotor Activity .
are shown in Figure 14.

Mean activity counts

Rats receiving U-50,488 alone had

significantly fewer activity counts on the test day than rats
treated with saline, pretreatment main effect, E (1,36) =
13.9, p < .001.

Thus, pretreatment with U-50,488 seemed to

induce a conditioned hypoactivity in 10-day-old rats.
17-day-Qld3

Locomotor Activitv Purina Cnnditionina .

Mean locomotor

activity counts of the U-50,488 and morphine-treated 17-day
old pups are presented in Figure 15.

As in Experiment 2, U

50,488 (2.0 mg/kg) treated rats had significantly more

locomotor activity counts than the saline-treated pups,
pretreatment main effect, E (1,28) = 26.71, p < .001.
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Rearing and Wall r-limbina Purina Conditioning .

Analyses of rearing and wall climbing did not reveal

significant effects/so the data is not presented.

Conditioned Placed Preference'.

The percentage and

total total time spent in the drug-paired compartment by
morphine-treated 17-day-old rats are presented in Figures 12
and 13.

Pups treated with 0.5 mg/kg morphine spent a

significantly greater percentage of time in the drug-paired
compartment than the control rats, t. (14) = 2.15, p < .05.

Similarly, pups treated with morphine alone spent

significantly more time in the drug-paired compartment than

the saline controls, p (14) = 2.38, p <.05.

This morphine-

induce preference was blocked by U-50,488, since rats treated

with both U-50,488 and morphine spent significantly less time

in the drug-paired compartment than rats receiving morphine
alone, Pretreatment x Posttreatment interaction, £ (1,28) =
6.14, p < .05, and Tukey tests (p < .05).

Conditioned Locomotor Activity .

Mean activity counts

on the test day are presented in Figure 16.

U-50,488-treated

17-day-old rats had significantly fewer test day activity
counts than rats treated with saline, pretreatment main

effect, E (1,28) = 8.05, p < .01.

Thus, like in the younger

pups, U-5Q,488 induced a conditioned hypoactivity.
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35-day-Qlds

Locomotor Activity During Conditioning .

Mean locoitiotor

activity counts of U-50,488 and morphine-treated 35-day-old
rats are shown in Figure 17.

Neither morphine nor U-5Q,488

affected locomotor activity.

.

Rearing and Wall Climbing Purina Conditioning .

Analyses of rearing and wall climbing did not reveal

sighificant effects, so the'data is not presented.
Conditioned Place Preference .

The percent and total

time spent in the drug-paired compartment by morphine-treated
35-day-old rats are shown in Figures 12 and 13.

Morphine

(0.5 mg/kg) did not induce a place preference in the
periadolescent rat.

Conditioned Locomotor Activity .

Mean activity counts

of 35-day-old rats on the test day are presented in Figure
18.

Treatment with U-50,488 or morphine did not affect

activity on the test day.
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FIGURE captions

Figure 9.

Mean number (+SEM) of line crosses in the drug-

paired compartment of the CPP apparatus during both
conditioning sessions .(30 min each).

The 10-day~old rats

were injected with U-50,488 (2 mg/kg, s.c.) or,saline 30 min

prior to conditioning, and:morphine . (0.5 m.g/kg i.p.)
immediately prior to conditioning (n = 8).

Figufg m.

Mean number (+SEM) of rearing counts ..in the drug-

paired compartment of the CPP apparatus during both
conditioning sessions (30 min each).

The 10-day-old rats

were treated as in Figure 9.

Figutd 11.

Mean number (+SEM) of wall climbing counts in the

drug-paired compartment of the CPP apparatus during.both,
conditioning sessions (30 min each).

The 10-day-old rats

were treated as, in Figure 9.

Figute—12.'

Mean percent time (+SEM) spent in the drug-paired

compartment of the CPP apparatus on the test day (n = 8).
The 10-, 17- and 35-day-.old rats were drug-free on the test

day and allowed 900 sec. access to the three compartments.
The percent score was determine as in Figure 2.

Figure—13..

Mean total (+SEM) time^ spent in the drug—paired

compartment of the CPP apparatus on the test day (n = 8).
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The 10-, 17- and 35-day-old rats were drug-free on the test
day and allowed 900 sec access to the three compartments.
Figure 14.

Mean number (+SEM) of line-crosses on the test

day (n = 8).

The 10-day-old rats were drug-free on the test

day and allowed 900 sec access to the three compartments.

Figure 15.

Mean number (+SEM) of line-crosses in the drug-

paired compartment of the CPP apparatus during both
conditioning sessions (30 min each).

The 17-day-old rats

were treated as in Figure 9 (n = 8).

Figure 1^.

Mean number (+SEM) of line-crosses on the test

day (n = 8).

The 17-day-old rats were drug-free on the test

day and allowed 900 sec access to the three compartments.

Figure 17.

Mean number (+SEM) of line-crosses in the drug-

paired compartment of the CPP apparatus during both
conditioning sessions (30 min each).

The 35-day-old rats

were treated as in Figure 9. (n = 8).

Figure 10.

Mean number, (+SEM) of line-crosses on the test

day, (n = 8). • The 17-day-old rats were drug-^free on the test
day and,allowed 900 sec access to the three compartments.
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EXPERIMENT 4

Numerous studies have shown that a series of changes in

gene transcription take place as: a cell responds to impinging
neural activity (Sheng & Grenberg, 1990).

An approach used

to identify neuronal activation is Fos immunocytochemistry
(Sagar et al./ 1988).

Recently, our laboratory demonstrated

that cocaine-induced CPP induces Fos in adult rats, and that

U-50,488 blocks this cocaine-induced neuronal activity
(Crawford et al., in press).

Hence, the purpose of this

Study was to determine the neuroanatomical pathways which
exhibit Fos activity in response to place preference
conditioning in the, preweanling and periadolescent rat.

It

was predicted that enhanced Fos activity would result from

morphine-induced place preference conditioning, an effect
that would be blocked by prior treatment with U-50,488.
Method

Subjects.

Subjects were the 96 male and female rats

from Experiment 3.

Procedure and Drugs.

Rats were anesthetized with

phenobarbital and rapidly perfused with 4% paraformaldehyde 2
hr after CPP testing.

Following a postfixation period,'100

|im sections were cut from each brain using a Vibratome 1000
(Ted Pella, Inc., Redding, OA).

Sections were washed three

times with 0.1 M phosphate buffer (PB) before being washed
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with an Endogenous Peroxidase Block (0.1 M PB containing
hydrogen peroxidase and methanol solution) for 10 min to
control for non-specific binding.

All sections were then

washed three times with PB before being incubated with the

Fos primary antibody at a 1:5,000 dilution in HSS (0.1 M PB

containing 2% horse serum, 0.1% triton-XlOO, and 0.1% bovine

serum albumin). Sections were incubated in the primary
antibody for 48-72 hrs.

Control sections from each rat were

run in the absence of the primary antibody.

All sections

were then washed three times in PB and,incubated with a

biotmylated mouse anti rat secondary antxbody for 2 hr
(1:1000 dilution in HSS).

Sections were washed three times

in PB and incubated for 2 hr in avidin—biotin—horseradish

peroxidase conjugate from ABC horse kits.

Sections were then

washed three more times and incubated with 3,3'

diaminobenzidine tetrahydrochloride and hydrogen peroxide.
After this procedure, sections were rinsed in PB and mounted

on chrom-alum slides.

The slides were then air dried,

dehydrated, and coverslipped with permount.

All washes

lasted 5 min each.

Coronal sections from the same brain region were then

selected from each rat quantitative analysis.

The number of

distinguishable immunoreactive nuclei present within specific
regions of the brain were manually counted using a
magnification of 40x.

At each selected region, one to three
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samples were be counted with the size of the sample area
being Imm^.

The primary antibody was a monoclonal antibody made to
the N-terminal end of the Fos molecule in mouse myeloma
cells.

This primary antibody recognizes Fos and not Fos

related antigens.

The secondary, antibody was a biotinylated

mouse-anti-rat secondary antibody purchased from Vector
Laboratories, Inc. (Burlingame, CA, USA).

An avidib-biotin

horseradish peroxidase conjugate from ABC horse kit was also

acquired from Vector Laboratories, Inc.

This general

procedure was based on the method described by Crawford et
al. (in press).

A total of 4-6 rats from each group were randomly chosen
for analysis of Fos immunoreactivity.

Similar coronal

sections from each rat were selected for quantitative
analysis.

The number of distinguishable immunoreactive

nuclei present within the thalamus (1.5 A), habenula (1..3 A),
hypothalamus (1.8 A), and the nucleus accumbens (1.7 A) were
manually counted using a magnification of 40x.

(The numbers

in parentheses represent sections anterior to bregma,
according to the rat brain atlas of Pellegrino & Cushman,
1967).

Statistical Analyses ,

Data from the

immunocytochemistry experiment were analyzed using a one—way
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ANOVA (for each brain region).

When appropriate, Tukey tests

(p < .05) were used for making post hoc comparisons.

Results

10-day-olda

Effects of Conditioned Place Preference on Fns

Immunoreactivity .

Mean number of Fos-positive nuclei in

various brain areas of rats are shown In Table 1.

Overall,

10-day-old rats pretreated with U-50,488 showed a decrease in
the amount of Fos-positive nuclei in the dorsomedial thalamus

and posterior hypothalamus, pretreatment main effect,

£ (1,17) = 4.38,

p <0.05, and pretfeatment main effect, ,

£ (1,17) = 7.59, p < 0.05, respectively.

In addition,

morphine-treated rats showed a significant increase in the
amount of Fos-positive nuclei in the thalamus, posttreatment
main effect, £ (1,17) = 6.53, p < 0.05.
17-day-olds

Effects of Conditioned Place Preference on Fo.q

Immunoreactivity .

The mean number of Fos-positive nuclei in

various brain areas of rats are shown in Table 2. Overall,
U-50,488 induced a significant decrease in the mean number of

Fos-positive nuclei in the habenula and posterior
hypothalamus of the 17-day-old rats, pretreatment main
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effect, E (1,13) = 5.25, ^ < 0.05, and pretreatment iria

effect, E (1/12) = 4.56,

p < 0.05, respectively.

35-day-old3

Effects of Conditioned Place Prp.ff.i-(^nce nn Fns

Iirmunoreactivity .

The mean number of Fos-positive nuclei in

various brain areas of rats bf 35-ciay-oid rats are shown in: \
Table 3.

Overall,vperiadolescent ratS; pretreated with

U-50,488 showed an increase in FOS-positive nuclei in the

thaiaimus,:pretreatment iriain effect, E (1,15).. = 7.15;, p <
0.05.

.-v

'v,.vV. .■

'it...;.'
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Table 1

Mean Number:of Fos-positive Nuclei in Various Brain Areas of

IQ-day-Old rats.

Numbers RenrfiSfint Counts From IniTn

2

^

lO-DAY-OLDS
00

0

SAL-SAL

Dorsomedial Thalamus

SAL-MORPH
00

. 9.503'^

16.50a

U50-SAL

4.88^'

U50-MORPH

10.66

Habehula

2.92

4.60

2.88

5.84

Posterior Hypothalamus

4.75a

5.90a

2.00

2.50

Nucleus Accumbens

1.67

2.42

1.72

^Significantly different from U-SO,488-treated rats,
pretreatment main effect (p < .05).

^^Significantly different:^ from morphine-treated rats,
pOsttreatment main effect (p < •05).
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Table 2

Mean Nuinber of Fos-positive Nuclei in Various Brain Areas of

17-day-Old rats.

Numbers Represent Connt.s From Imm

2

_

17-DAY-GLDS

SAL-SAL

U50-SAL

U50-MORPH

6.25

5.25

7.10

10.50a

4.25a

2.62

1.60

Posterior Hypothalamus

7.25a

7.84a

3.50

2.90

Nucleus Accumbens

3.11

2.78

0.83

2.20

Dorsomedial Thalamus
Habenula

SAL-MORPH

9.88

^Significantly different from U-50,488-treated rats,
pretreatment main effect (p < .05).
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Table 3

Mean Number of Fos-positive Nuclei in Various Brain Areas of

35-d,ay-Qld rats.

Numbers Represent Counts From 1mm

^ Area.

35-DAY-OLDS
SAL-SAL

SAL-MORPH

Dorsomedial Thalamus

5.883

7.903

Habenula

1.80

Posterior Hypothalamus
Nucleus Accumbens

U50-SAL

U50-MORPH

12.00

11.
.10

2,
.00

2.10

,84
5.

7.40

7,
.00

7.80

8,
.40

1.75

5,
.25

3.40

.07
3.

^Significantly different from U-50,488--treated rats.
pretreatment main effect (p < .05),
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DISCUSSION

The purpose of the present study was to examine the

effects of opioid agonists in the preweanling and

periadolescent rat to further assess the neuropharmacology of
reward.

To that end, morphine-induced GPP was assessed in

10-,.17- and 35-day-old rats after treatment with the kappa
agonist U-50,488.

In addition, the neuronal response to CPP

conditioning was examined by measuring the induction ofFos,
the protein product of the early response gene c-fos.
As expected, preweanling rats spent significantly more

time in the environment paired with 0.5 mg/kg morphine,
indicating that morphine was rewarding (see also Bozarth &

Wise, 1980; Funada, Suzuki, Narita, Misawa, & Nagase, 1993;
Kehoe & Blass, 1986b; Randall et al., 1992; Wise, 1989; Wise
& Bozarth, 1982).

Pretreatment with U-50,488 attenuated the

preference for the morphine-paired environment, indicating
that kappa agonists are effective at blocking the conditioned
effects of morphine in the 10- and 17-day-old rat.

This

effect appeared to be due to a diminution of morphine's
rewarding properties, since U-50,488 alone did not avert rats

from the drug-paired compartment.

The latter point is

important, since kappa agonists have been reported to induce
place aversions in adult and preweanling rats (Barr, 1993;
Funada et al., 1993; Shippinberg & Herz, 1987).

In the

preweanling rat, U-50,488's aversive effects appear to be
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dose^dependent, as lower doses of U-50,488 (2-3 mg/kg) are

witHout significant aversive properties in 3--, 10-, and 17^
day-olds (Barr, 1993, Barr, Wang, & Garden, 1994; and the
present study).

The issue of aversiveness becomes critical

for the interpretation Of these findings/ b

a 0-50,488

induced aversion could have been used to explain why rat pups
spent less time in the morphine-paired compartment.

Morphine did not induce GPP in the 35-day-old rats, as
morphine-treated rats responded similarly to their saline

controls.

Morphine's inability to induce GPP in the 35-day

old rats may be due to age-dependent differences in drug
responsiveness.

For example, periadolescent rats are less

sensitive to morphine and amphetamine than younger or older
rats (Bauer & Duncan, 1975; Gaza & Spear, 1980; Spear &
Brake, 1983).

In addition, doses of cocaine that are

reinforcing in preweanling and adults rats are less

reinforcing in the periadolescent animal (Laviola et al.,
1992; Spear, 1979, 1990).

The mechanisms responsible for

this age-dependent effect are uncertain, but it may be due to
the maturation of DA autoreceptors in the mesolimbic pathway
(Shalaby & Spear, 1980; Spear & Brake, 1983).

; The pathways mediating reward processes have been at

least partially delineated.

More specifically, feelings of

reward appear to be correlated with activity in the

•

mesolimbic DA pathway, which projects from the ventral
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tegmental area (VTA) to the nucleus accurrtbens (Di Chiara &

North/ 1992; Fallen, l988).

Both the psychomotor stimulants

and. the mu opioids induce reward by activating this pathway,
but these drugs do it in quite different ways.

For example,

cocaine ahd amphetamine act directly in the nucleus accumbdhs:
to increase synaptic DA; whereas, heroin and morphine :

indirectly activate the mesolimbic DA fibers by disinhibiting
GABA interneurons in the VTA (Di Chiara & Imperato, l987; Di

Chiara & North, 1992; Wise, 1988; Wise & Rompre, 1989).

Kappa opioid drugs presumably block reward by directly

inhibiting DA release in the nucleus accumbens (Spanagel,
Herz, & Shippenberg, 1992).

■ ■ ■ The pathways mediating the effects of rewarding drugs
have also been mapped by using early genes as neuronal

markers (Crawford et al., in press; Graybiel et al., 1990;

Sagar et al., 1988)

Thus, on the preference test day (i.e.,

when in a non-drug state), rats were tested for Fos

immunoreactivity in order to determine those brain areas

activated during the expression of CPP.

Unexpectedly, drug-

and saline-treated (control) rats showed Fos immunoreactivity
in the dorsomedial thalamus, posterior hypothalamus, and the

habenula.

The pattern of neuronal activation exhibited by

these preweanling rats is not consistent with previous

findings in adults (Crawford et al., in press; Graybiel et
al., 1990; Young et al., 1991).
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For example, Crawford et al.

(in press) have shown that the expression of cocaine-induced

CPP increases Fos immunoreactivity in the anterior cingulate
cortex, piriform cortex, lateral septal area, and olfactory
tubercles, without affecting baseline levels of Fos in the

control animals.

In contrast, preweanling rats showed

moderate levels of Fos activity after both drug and saline
treatment (see Tables 1-3).

The reasons for the inconsistent Fos data are uncertain,

however three possibilities are apparent: first, it is
possible that morphine does not readily induce Fos; second,
young rats may exhibit high levels of non-specific Fos

activity; and third, the odor used on the test day may be
sufficient to substantially increase Fos.

The first

possiblity seems unlikely since morphine has been shown to

increase Fos activity in adult, rats, albeit at much higher
doses (Liu, Nickolenko, & Sharp, 1994).

The second

possibility, that immature animals have high baseline levels
of Fos, may have some validity, since growth factors are

known to induce C-fos activity (Alberts et al., 1989, pp.

756-757). Although speculative, it would not be surprising
if odor induced Fos activity, because Morgan and Curran
(1991) have found that a variety of non-specific stimuli
(e.g., electrical stimulation, heat stress, kainic acid
lesions, and nociceptive stimuli) are sufficient to induce

Fos.

Consistent with this, the brain areas showing the
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greatest nuirnber of Fos-positive;

(e.g., the habenula

and the dorsomedial thalamus) are components of the olfactory

,system (Barf, 1979;'M

1989).

So odor, ah important

source of sensory information for the preweanling rat, may
have induced high levels of Eos activity, which masked the
■■

conditioned effects of morphine.

■ A very interesting aspect of this study involved

drug-induced effects during conditioning.

Surprisingly,

acute treatment with the kappa agonist U-50,488 markedly

increased the locomotor activity of 10- and 17-day-old rats,
an effect partially blocked by morphine (see Figures 10 and

11)

Consistent with this, U-50,488 increased the rearing

and wall climbing of 10-day-old rats.

These results are in

contrast to studies using adult rats which typically:find

decreased activity after U-50,488 treatment (Crawford et al.,
in press; Di Chiara & Imperato, 1987; Spanagel et al., 1992),
On the other hand, U-50,488 did not affect the locomotor

activity of 35-day-old rats.

The inability of U-50,488 to

increase the activity of 35-day-olds may indicate that
periadolescent rats are generally less sensitive to

pharmacological challenge than younger or older rats (Bauer &

Duncan, 1975; Infurna & Spear, 1979; Shalaby & Spear, 1980;
Spear & Brick, 1979; Spear, Shalaby, & Brick, 1980).
Alternatively, the lack of a U-50,488-induced increase in
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activity may simply reflect that 35-day-olds are responding
similar to adults.

In adults/ activatidn of the kappa opidid receptor is
generally associated with a decrease in locomotor activity
(Crawford et al

in press; Di Chiara & Imperato, 1987;

Matsumoto,, Brinsfield, Patrick, & Walker, 1988).

For

example, the kappa opioid receptor agonist U-50,488 blocks

cocaine-induced locomotor activity and induces behavioral
depression in mature rats and mice (Crawford et al., in
press; Crawford et al., 1994; Di Chiara & Imperato, 1987;

Jackson & Cooper, 1986; Leighton, Johnson, Meecham, Hill, &
Hughes, 1987).

These actions are thought to be due to a

kappa-mediated reduction of DA release in the nucleus

accumbens (Crawford et al., 1994; Di Chiara & North, 1992;

Spanagel et al., 1992).

If this explanation is accurate, it

makes the results of the present study even more surprising,
since U-50,488 increased the locomotor activity of the
preweanling rats.

Locomotor activity, as well as rearing and

wall climbing, are known to be DA.mediated, so it is possible
that the kappa opioid system is somehow activating the DA

pathway in preweanling rats.• Thus, these data suggest that

U-50,488 enhances DA functioning in the preweanling rat,
while it depresses DA functioning in the adult rat.
In contrast to U-50,488's activating effects, morphine
(0.5 mg/kg), a mu opioid receptor agonist, did not affect the
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iocomotor activity of 10- and 17-day-old rats.

This was not

surprising since low to moderate doses of morphine (0.5, 1.0,

and 5.0 mg/kg) often have sedative effects in preweanling
rats (Caza & Spear, 1980).

Interestingly, morphine was able

to produce its rewarding effects without inducing

hyperactivity.1

finding is potentially of great

;

importance, since it has been postulated that the rewarding/
and psychomotor stimulant properties of addictive drugs are
mediated by the same biological mechanisms (see Wise &
Bozarth, 1987, for review).

For example. Wise and Bozarth

(1987) contend that increased Iocomotor activity is an

integral part of a drug's rewarding properties.

This appears

not to be the case in the preweanling rat, since morphine was

sbie to induce CPP without producing Iocomotor activity, and
U-50,488 was able to increase Iocomotor activity while

attenuating

morphine's rewarding effects.

Therefore, /it' ; ^

seems that in the preweanling rat reward processes and

Iocomotor activity can be dissociated in the preweanling rat.
This property may make the preweanling rat an excellent model
for studying reward processes.

As expected, morphine did not affect the Iocomotor

activity of the 35-day-old rats.

This lack of effect may

have been due to age-dependent changes in a variety of
neurobiological systems, maturation of the blood brain

barrier (Caza & Spear, 1980), or an insufficient dose of
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morphine.

The latter explanation seems unlikely however,

since periadolescent rats do not show an increase or decrease

in baseline activity when given 0.1, 0.5, l.Oy or lO mg/kg
ymprphine (Gaza & Spear, 1980).;
:

v

Pverall, ths fact that 35-day-61d rats showed a lack of

responsiyeness to both U-50,488;and morphine is intriguing

;

and: may indicate that those neurobiological systems Critical■

fdr reward are in a transitionai deveibpmental phase during
the periadolescent;period.: The inability of U--50, 488 er

^

morphine to induce behaviofal 'changes in the 3'5-day-pld may

be due to the development pfautoreGeptors in the mesolimbic
pathway, resulting in a temporary.decrease in the sensitivity
of the DA projectidns; during the periadolescent peripd (Spiear
& Brake, 1983) .

Thus,, these findings may indicate that the

"paradoxical" responses exhibited by periadolescents are due
to a catecholaminergic hyposensitivity during this
developmental period.

Another unexpected result was that U-50,488 induced

conditioned hypoactivity on the test day in both the I0- arid

IV-day-old rats.

The reasons for these results are unclear,

however it is possible that acute treatment with U-50,488 had
both locomotor activating properties and was somewhat

aversive.

Conditioned activity, which is often observed

after treatment with reinforcing drugs, is thought to be due
to the conditioned release of DA (Kiyatkin, 1993)
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Although

speculative, it is possible that conditioned hypoactivity,
which occurred after treatment with U~50,488, may be due to a
conditioned inhibition of DA release.

The present results are generally consistent with other

developmental psychopharmacological studies showing that as
the animal matures, new behaviors emerge as the underlying
neurobiological mechanisms become functional (see Spear,
1979; Zolman & McDougall, 1983, for additional reviews).
More specifically, previous studies have shown that the

behavior-activating properties of drugs are often

quantitatively greater in older animals (McDougall, Arnold &
Nonneman, 1990, McDougall, Duke, Bolanos, & Crawford, 1994;
Shalaby & Spear, 1980).

Qualitative differences are also

occasionally apparent, as some drug-induced behaviors (e.g.,
grooming) emerge at various times during the preweanling
period, while other behaviors (e.g., wall climbing) only
occur during a restricted period (Moody & Spear, 1992;
Shalaby & Spear, 1980).

In the present study, examples of both quantitative and
qualitative ontogenetic differences were evident.

For

example, morphine had quantitatively different effects on the

GPP performance of young and adult rats.

More specifically,

doses greater than 0.5 mg/kg were unable to induce GPP in the

preweanling rat, whereas 2-5 mg/kg is often used to induce

GPP in the adult (Mackey & van der Kooy, 1984; Randall et
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al., 1992/..Reid, Marglin, Mattie, & Hubbell, 1988).

More

importantly, a number of age-dependent qualitative behavioral

differences were also observed in the present study.

An

excellent example is the lack of drug responsiveness

exhibited by periadolescent rats.

However, the most dramatic

qualitative differences involved U-50,488 and activity, as
U-50,488 induced a dose-dependent increase in the locomotor

activity of preweanling rats.

In contrast, similar doses of

U-50,488 decrease the locomotor activity of adults (Crawford

et al., in press; Di Chiara & Imperato, 1987; Jackson &

Cooper, 1986).

These finding are of special importance,

because they indicate that the pattern of kappa/DA

interactions are profoundly different in the young and adult
rat.

Presumably, this age-dependent difference can be used

as a tool for further understanding how the kappa opioid and
DA systems interact to mediate behavior.
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